Skip to main content
Premium Trial:

Request an Annual Quote

Recent Key Deals Between RNAi Drug Developers and Big Pharma/Biotech

Premium
Eli Lilly management last week highlighted the most promising drug candidates in the company’s pipeline, including two antisense-based drugs currently in the clinic for cancer (see related story, this issue). Despite Lilly’s early look at the RNAi field though its now-expired 2004 collaboration with Sirna Therapeutics, the drugs giant has yet to embrace RNAi as a therapeutic modality.
 
Other big players in the pharmaceutical, biotech, and medical device fields, however, have taken steps to incorporate RNAi into their drug-development efforts. Below is a snapshot of key alliances between big pharma/biotech and RNAi firms.
 

File Attachments
The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.